Business

In future, hospitals should be able to sequence patient DNA swiftly and cheaply. Rex Dalton reports on the firms bringing that day closer.

Lack of regulation and risk assessment could hamper the nanotechnology sector. Virginia Gewin reports.

Pharmaceuticals made in genetically modified animals have been poised to take off for years. Heidi Ledford investigates the reality.

Women academics are less likely than men to take out patents. Emma Marris investigates the reasons why.

Biotechnology companies come in many shapes and sizes, but, say two economists, the ones with the widest spread of skills in their teams stand the best chances of success. Aaron Bouchie reports.

Young blood is taking the helm at the world's biggest drug firm. Colin Macilwain assesses whether this is likely to revive its share price.

A technique for turning genes off has sparked a flurry of biotech investment. Erika Check investigates.

For big oil companies, carbon dioxide is waste; for people who grow fruit, it's a valuable commodity. Ned Stafford reports on a marriage of convenience in the Netherlands.

Traditional medicine has spent decades in the wings of pharmacology. Now India is pushing it to centre stage, as K. S. Jayaraman reports.

The first foreign-based biotech company to list its shares in Japan has been caught up in bureaucracy — but its experience should help others. Ichiko Fuyuno reports.